Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 95.4% in April

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 153,400 shares, an increase of 95.4% from the March 31st total of 78,500 shares. Based on an average daily volume of 648,100 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upgraded shares of Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 16th.

Avalo Therapeutics Trading Up 6.4 %

NASDAQ:AVTX traded up $0.96 during trading hours on Friday, reaching $15.94. 78,226 shares of the company traded hands, compared to its average volume of 296,189. The business’s 50-day moving average price is $9.42 and its two-hundred day moving average price is $13.33. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $1,130.40. The stock has a market capitalization of $16.48 million, a P/E ratio of -0.03 and a beta of 1.15.

Institutional Trading of Avalo Therapeutics

An institutional investor recently bought a new position in Avalo Therapeutics stock. Acadian Asset Management LLC bought a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 283,306 shares of the company’s stock, valued at approximately $34,000. Acadian Asset Management LLC owned approximately 1.40% of Avalo Therapeutics at the end of the most recent quarter. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.